Liposomes as Carriers of Drugs Observations on Vesicle Fate after Injection and Its Control
- 68 Downloads
Detailed knowledge of the behavior of liposomes (phospholipid vesicles) after injection is a prerequisite for their successful application as drug carriers in the therapy, prevention, or detection of disease (Gregoriadis, 1980). This discussion deals with two aspects: (1) the extent to which vesicles retain entrapped agents in the presence of biological fluids, namely, blood and (2) the rate by which vesicles are cleared from the circulation and their distribution in tissues. Evaluation of the first is likely to lead to methods of preventing or reducing agent leakage from the carrier en route to its target site. Study of the second aspect will contribute to the elucidation of the mechanism(s) through which vesicles leave the circulation to end up in tissues and also allow manipulations controlling vesicle clearance or uptake by tissues in need of pharmacological intervention. Both aspects have been discussed in detail elsewhere (Gregoriadis, 1983; Gregoriadis et al, 1983; Senior, 1987).
KeywordsCholesterol Content Vesicle Size Plasma High Density Lipoprotein Unilamellar Liposome Multilamellar Liposome
Unable to display preview. Download preview PDF.
- Gregoriadis, G. (ed.), 1984, Liposome Technology, Vols. 1–3, CRC Press, Boca Raton, FL.Google Scholar
- Gregoriadis, G. (ed.), 1988, Liposomes as Drug Carriers: Recent Trends and Progress, Wiley, Chichester.Google Scholar
- Gregoriadis, G., Kirby, C., and Senior, J., 1983, Optimization of liposome behaviour in vivo. Biol. Cell 47:11–18.Google Scholar
- Gregoriadis, G., Garcon, N., Senior J., and Davis, D., 1988, The immunoadjuvant action of liposomes: Nature of immune response and influence of liposomal characteristics, in Liposomes as Drug Carriers: Recent Trends and Progress (G. Gregoriadis, ed.), pp. 279–307, Wiley, Chichester.Google Scholar
- Krupp, L., Chobanian, A. V., and Brecher, J. P., 1977, The In viov transformation of phospholipid vesicles to a particle resembling HDL in the rat. Biochem. Biophys. Res. Commun. 722:1251–1258.Google Scholar
- Leserman, L. D., Machy, P., Deraux, C., and Barbet, J., 1983, Antibody-bearing liposomes: Targeting in vivo. Biol. Cell 47:111–116.Google Scholar
- Roerdink, F., Regts, J., Daemen, T., Bakker-Woudenberg, I., and Scherphof, G., 1986, Liposomes as drug carriers to liver macrophages: Fundamental and therapeutic aspects, in Targeting of Drugs with Synthetic Systems (G. Gregoriadis, J. Senior, and G. Poste, eds.), pp. 193–206 Plenum Press, New York.Google Scholar
- Senior, J., 1987, Fate and behaviour of liposomes in vivo: A review of controlling factors. CRC Crit. Rev. Therapeutic Drug Carrier Systems 3:123–193.Google Scholar
- Senior, J., and Gregoriadis, G., 1984, Methodology in assessing liposomal stability in the presence of blood, clearance from the circulation of injected animals and uptake by tissues, in Liposome Technology (G. Gregoriadis, ed.), pp. 264–282, CRC Press, Boca Raton, FL.Google Scholar